NEXIEN BIOPHARMA, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0163 USD | 0.00% |
|
0.00% | -37.07% |
Valuation
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 173.3 | 4.816 | 2.634 | 5.008 | 3.783 | 2.289 |
| Enterprise Value (EV) 1 | 172.5 | 4.67 | 2.636 | 5.003 | 3.887 | 2.525 |
| P/E ratio | -131 x | -1.07 x | -0.99 x | -2.67 x | -5.77 x | -6.16 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | -490 x | -5.96 x | -1.84 x | -10.4 x | -21.9 x | 85.7 x |
| FCF Yield | -0.2% | -16.8% | -54.2% | -9.61% | -4.56% | 1.17% |
| Price to Book | 148 x | 18.1 x | -417 x | -365 x | -32.2 x | -9.08 x |
| Nbr of stocks (in thousands) | 43,881 | 53,511 | 53,984 | 55,772 | 60,522 | 64,022 |
| Reference price 2 | 3.950 | 0.0900 | 0.0488 | 0.0898 | 0.0625 | 0.0358 |
| Announcement Date | 28/09/18 | 30/09/19 | 28/09/20 | 12/10/21 | 28/09/22 | 28/09/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -1.283 | -3.933 | -2.637 | -1.844 | -0.564 | -0.2826 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -1.283 | -4.301 | -2.672 | -1.86 | -0.6264 | -0.3619 |
| Net income 1 | -1.283 | -4.301 | -2.672 | -1.86 | -0.6264 | -0.3619 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -0.0301 | -0.0843 | -0.0495 | -0.0336 | -0.0108 | -0.005805 |
| Free Cash Flow 1 | -0.3519 | -0.7837 | -1.429 | -0.4806 | -0.1774 | 0.0295 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 28/09/18 | 30/09/19 | 28/09/20 | 12/10/21 | 28/09/22 | 28/09/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 0 | - | 0.1 | 0.24 |
| Net Cash position 1 | 0.82 | 0.15 | - | 0.01 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -0.35 | -0.78 | -1.43 | -0.48 | -0.18 | 0.03 |
| ROE (net income / shareholders' equity) | -147% | -593% | -2,059% | 18,470% | 954% | 196% |
| ROA (Net income/ Total Assets) | -78.4% | -311% | -988% | -4,769% | -470% | -211% |
| Assets 1 | 1.637 | 1.385 | 0.2703 | 0.039 | 0.1333 | 0.1717 |
| Book Value Per Share 2 | 0.0300 | 0 | -0 | -0 | -0 | -0 |
| Cash Flow per Share 2 | 0.0200 | 0 | 0 | 0 | 0 | 0 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 28/09/18 | 30/09/19 | 28/09/20 | 12/10/21 | 28/09/22 | 28/09/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -37.07% | 11L | |
| +30.81% | 68TCr | |
| +30.35% | 59TCr | |
| -3.62% | 36TCr | |
| +18.08% | 33TCr | |
| +4.04% | 28TCr | |
| +15.53% | 24TCr | |
| +10.16% | 21TCr | |
| -8.14% | 20TCr | |
| +8.39% | 17TCr |
- Stock Market
- Equities
- NXEN Stock
- Financials Nexien BioPharma, Inc.